news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

hello everyone! a new trading week has begun. let's pay attention to the market conditions and latest information in the morning~

on september 2, a-shares opened in the red in the morning: the shanghai composite index was at 2832.35 points, down 0.35%; the shenzhen component index fell 0.2%, and the chinext index fell 0.19%. the market decline widened in the morning. as of press time, the shenzhen component index fell more than 1%, and the chinext index fell nearly 2%.

on the market, precious metals, liquor, automobiles, food and other sectors were sluggish in the morning, and concepts such as the mao index, china shipbuilding corporation, large infrastructure central enterprises, gold and jewelry all fell; there were local market conditions in industries such as coal, forestry, soft drinks, and gas.

the three major hong kong stock indexes opened lower in the morning: the hang seng index fell 0.7%, the hang seng tech index fell 0.58%, and the hang seng china enterprises index fell 0.82%. as of press time, the three major indexes fell by more than 1%; new world development fell more than 14% during the session, leading the decline in the hang seng index.

see the details——

chairman detained

naike equipment fell nearly 16%

on the morning of september 2, naike equipment opened at 23 yuan per share, a drop of 11.4%. after the opening, naike equipment's stock price continued to fall, falling to 21.82 yuan per share at one point, a drop of nearly 16%.

after the market closed on august 30, naike equipment issued an announcement stating that it had received a notice on the same day from the family of huang mingjiu, one of the company's actual controllers, chairman and legal representative, that huang mingjiu's family received the "detention notice" and "case filing notice" issued by the tongling city tongguan district supervisory committee on august 29. huang mingjiu was detained and a case was filed for investigation.

naike equipment said that up to now, the company's control has not changed, the board of directors is operating normally, and the production and operation management are normal. this matter will not have a significant impact on the company's normal production and operation. the company has not yet been informed of the progress and conclusion of the investigation, and will continue to pay attention to the follow-up of the above matter, and promptly fulfill its information disclosure obligations and remind relevant risks.

according to information disclosed by naike equipment, huang mingjiu was born in 1962, is 62 years old, has chinese nationality, and does not have permanent residence abroad. according to the 2023 annual report of naike equipment, huang mingjiu serves as the company's chairman and core technical personnel. the term of office of chairman is from june 2020 to june 2026. the total pre-tax remuneration received from the company during the reporting period is approximately 804,800 yuan. as of the end of june this year, huang mingjiu held 3.9871 million shares of naike equipment, accounting for 4.86% of the total share capital.

stem cell concept strengthens

guanhao biotechnology 20cm daily limit

on the morning of september 2, a-share stem cell concepts rose, guanhao bio hit the 20cm daily limit, nanhua bio hit the daily limit, zhongyuan xiehe hit the daily limit; tailin bio, chitianhua, nanjing xinbai and others rose.

last month, the beijing municipal drug regulatory half-year work conference was held, at which the work of issuing the country's first stem cell drug production license was particularly affirmed. the issuance of this drug production license indicates that the relevant companies have obtained the legal qualifications and capabilities to produce stem cell drugs.

in addition, the 3rd tianfu stem cell and cell therapy conference will be held from september 6 to 8. it is reported that the conference will focus on cutting-edge scientific issues in the fields of biomedicine and stem cells with the theme of "collaborative innovation of medical science and technology and integrated development of health industry", and will showcase the latest research results and important progress in the fields of biomedicine and stem cells.

minsheng securities research report believes that domestic stem cell drugs have ushered in major policy benefits. from the initial formation of a huge market scale as a medical service supervision, to the comprehensive suspension of stem cell treatment, and then to the release of a large number of technical guidelines in the past two years to mainly regulate in the form of drugs, my country's research and development of new stem cell drugs has accelerated. from 2020 to the present, a large number of technical guidelines for supporting stem cell drugs have been issued, from preclinical pharmaceutical research guidelines for stem cell drugs, clinical research guidelines, and even clinical research guidelines focusing on specific indications of stem cells, indicating the application path and standards for stem cell drugs to pharmaceutical companies. since 2020, the number of stem cell drug inds applied by domestic pharmaceutical companies has doubled, and many stem cell drugs have entered phase iii clinical trials.